Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines

Cancer Science

Volumn 99, Issue 11, 2008, Pages 2315-2326

  Inoue, Hiroyuki ^a   Iga, Mutsunori ^a   Nabeta, Haruka ^a   Yokoo, Tomoko ^a   Suehiro, Yoko ^a   Okano, Shinji ^a   Inoue, Makoto ^b   Kinoh, Hiroaki ^b   Katagiri, Toyomasa ^c   Takayama, Koichi ^a   Yonemitsu, Yoshikazu ^a   Hasegawa, Mamoru ^b   Nakamura, Yusuke ^c   Nakanishi, Yoichi ^a   Tani, Kenzaburo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b University of Tokyo   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TUMOR VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY TEST; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SENDAI VIRUS; SPLEEN CELL; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FEMALE; GENE THERAPY; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; SENDAI VIRUS; TRANSDUCTION, GENETIC;

EID: 55449114286     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00964.x     Document Type: Article

References (53)

1. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-43.
2. Mach N, Dranoff G. Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 2000; 12: 571-5.
3. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002; 188: 147-54.
4. Tazi A, Bouchonnet F, Grandsaigne M, Boumsell L, Hance AJ, Soler P. Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. The J Clin Invest 1993; 91: 566-76.
5. Inaba K, Inaba M, Romani N et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176: 1693-702.
6. Miller G, Pillarisetty VG, Shah AB, Lahrs S, Xing Z, DeMatteo RP. Endogenous granulocyte-macrophage colony-stimulating factor overexpression: In vivo results in the long-term recruitment of a distinct dendritic cell population with enhanced immunostimulatory function. J Immunol 2002; 169: 2875-85.
7. Steinman RM, Witmer-Pack M, Inaba K. Dendritic cells: Antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 1993; 329: 1-9.
8. Ellem KA, O'Rourke MG, Johnson GR et al. A case report: Immune responses and clinical course of the first human use of granulocyte/ macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 1997; 44: 10-20.
9. Soiffer R, Lynch T, Mihm M et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998; 95: 13.141-6.
10. Simons JW, Jaffee EM, Weber CE et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex.vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57: 1537-46.
11. Tani K, Azuma M, Nakazaki Y et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: Clinical and immunological findings. Mol Ther 2004; 10: 799-816.
12. Simons JW, Mikhak B, Chang JF et al. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex.vivo gene transfer. Cancer Res 1999; 59: 5160-8.
13. Jaffee EM, Hruban RH, Biedrzycki B et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J Clin Oncol 2001; 19: 145-56.
14. Salgia R, Lynch T, Skarin A et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003; 21: 624-30.
15. Nagai Y. Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Rev Med Virol 1999; 9: 83-99.
16. Markwell MA, Svennerholm L, Paulson JC. Specific gangliosides function as host cell receptors for Sendai virus. Proc Natl Acad Sci USA 1981; 78: 5406-10.
17. Bitzer M, Armeanu S, Lauer UM, Neubert WJ. Sendai virus vectors as an emerging negative-strand RNA viral vector system. J Gene Med 2003; 5: 543-53.
18. Yonemitsu Y, Kitson C, Ferrari S et al. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 2000; 18: 970-3.
19. Moyer SA, Baker SC, Lessard JL. Tubulin: A factor necessary for the synthesis of both Sendai virus and vesicular stomatitis virus RNAs. Proc Natl Acad Sci USA 1986; 83: 5405-9.
20. Kaneda Y, Nakajima T, Nishikawa T et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002; 6: 219-26.
21. Li HO, Zhu YF, Asakawa M et al. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol 2000; 74: 6564-9.
22. Yoneyama Y, Ueda Y, Akutsu Y et al. Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells. Biochem Biophys Res Commun 2007; 355: 129-35.
23. Inoue M, Tokusumi Y, Ban H et al. Nontransmissible virus-like particle formation by F-deficient sendai virus is temperature sensitive and reduced by mutations in M and HN proteins. J Virol 2003; 77: 3238-46.
24. Abe J, Wakimoto H, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H. Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: Comparison of adenovirus- and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol 1995; 121: 587-92.
25. Shibata S, Okano S, Yonemitsu Y et al. Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-β gene. J Immunol 2006; 177: 3564-76.
26. Rubio V, Stuge TB, Singh N et al. Ex.vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003; 9: 1377-82.
27. + T cells by a flow cytometric assay for degranulation. J Immunol Meth 2003; 281: 65-78.
28. + effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J Immunol 2007; 179: 7365-75.
29. Vertuani S, De Geer A, Levitsky V, Kogner P, Kiessling R, Levitskaya J. Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes. Cancer Res 2003; 63: 8006-13.
30. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-5.
31. Murtaza A, Kuchroo VK, Freeman GJ. Changes in the strength of co-stimulation through the B7/CD28 pathway alter functional T cell responses to altered peptide ligands. Int Immunol 1999; 11: 407-16.
32. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in.vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000; 60: 3239-46.
33. Nakazaki Y, Hase H, Inoue H et al. Serial analysis of gene expression in progressing and regressing mouse tumors implicates the involvement of RANTES and TARC in antitumor immune responses. Mol Ther 2006; 14: 599-606.
34. Ellyard JI, Simson L, Parish CR. Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens 2007; 70: 1-11.
35. + T cells in the antitumor immune response. J Exp Med 1998; 188: 2357-68.
36. Chu Y, Xia M, Lin Y et al. Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF. Cancer Gene Ther 2006; 13: 510-19.
37. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995; 181: 619-29.
38. + T cells eliminate MHC class II-negative cancer cells in.vivo by indirect effects of IFN-γ. Proc Natl Acad Sci USA 1999; 96: 8633-8.
39. + dendritic cells expressing indoleamine 2,3-dioxygenase. J Immunol 2001; 167: 708-14.
40. Hirano T. Interleukin 6 and its receptor: Ten years later. Int Rev Immunol 1998; 16: 249-84.
41. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003; 22: 3188-92.
42. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev 2003; 3: 35-45.
43. Gilboa E. The promise of cancer vaccines. Nat Rev 2004; 4: 401-11.
44. Hege KM, Jooss K, Pardoll D. GM-CSF gene-modified cancer cell immunotherapies: Of mice and men. Int Rev Immunol 2006; 25: 321-52.
45. Kurooka M, Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 2007; 67: 227-36.
46. Suzuki H, Kurooka M, Hiroaki Y, Fujiyoshi Y, Kaneda Y. Sendai virus F glycoprotein induces IL-6 production in dendritic cells in a fusion-independent manner. FEBS Lett 2008; 582: 1325-9.
47. Iwadate Y, Inoue M, Saegusa T et al. Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats. Clin Cancer Res 2005; 11: 3821-7.
48. Kinoh H, Inoue M, Washizawa K et al. Generation a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases Gene Ther 2004; 11: 1137-45.
49. Vereecque R, Saudemont A, Wickham TJ et al. Gamma-irradiation enhances transgene expression in leukemic cells. Gene Ther 2003; 10: 227-33.
50. Stevens CW, Zeng M, Cerniglia GJ. Ionizing radiation greatly improves gene transfer efficiency in mammalian cells. Human Gene Ther 1996; 7: 1727-34.
51. Zeng M, Cerniglia GJ, Eck SL, Stevens CW. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation. Human Gene Ther 1997; 8: 1025-32.
52. Teh BS, Aguilar-Cordova E, Vlachaki MT et al. Combining radiotherapy with gene therapy (from the bench to the bedside): A novel treatment strategy for prostate cancer. Oncologist 2002; 7: 458-66.
53. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64: 6337-43.